Novo Nordisk shares fell about 8% in both Copenhagen and New York on Monday, September 21, 2026, the day of its London Capital Markets Day, according to GEN. BMO Capital Markets analyst Evan Seigerman wrote that Novo is "targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors," and noted that consensus already models about 3.53% annual growth for Novo against roughly 3.65% for pharma peers, so the target appeared priced into Wall Street estimates. The company used the event to set 2030 ambitions that included more than five potential blockbuster launches.
Novo Nordisk set out its 2030 ambitions at its Capital Markets Day in London on Monday, September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and deliver 2026-2030 revenue growth in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035, and it said the ambitions are not financial guidance. Shares fell as much as 9% and were down 4.7% by 11:24 GMT, BNN Bloomberg reported, as management faced questions on pricing and dealmaking. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned to launch in oral and injectable forms at the same time; BNN Bloomberg also reported a plan to scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by the end of the decade.
Novo Nordisk announced on Thursday, September 17, 2026 that the EMA's CHMP recommended marketing authorization for FREHEMGO (denecimig) to treat hemophilia A, with or without inhibitors, in adults and children. Denecimig is a factor VIIIa-mimetic bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of activated factor VIII. Novo says it is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks, and once-weekly prophylaxis in a single-use pre-filled pen. The application was based on the FRONTIER2, FRONTIER3, and FRONTIER4 trials, and FRONTIER5 showed no new safety signals in patients switching from emicizumab. Pending a European Commission decision, Novo expects launches in the first European countries in Q4 2026 and across the EU starting early 2027.
Orbis Medicines, based in Copenhagen and Lausanne, announced on Thursday, September 17, 2026 a multi-target discovery and license agreement with Novo to design oral macrocycle drugs for undisclosed cardiometabolic targets. Orbis can receive up to $1.4 billion in upfront and development and commercial milestone payments plus tiered royalties, and Novo will make a strategic investment of undisclosed size. The work uses Orbis's nGen platform, which combines generative AI, high-throughput synthesis, and a multi-parameter optimization engine trained on the company's experimental macrocycle data. Orbis chief executive Morten Graugaard said its synthetic macrocycles have reached up to 18% oral bioavailability in preclinical studies. Orbis launched in January 2025 with a €90 million (about $93 million) Series A led by NEA, with Lilly Ventures, Forbion, and Novo Holdings among its investors.
Novo will hold its Capital Markets Day in London on Monday, September 21, 2026, with CEO Mike Doustdar presenting the corporate strategy. A TIKR preview published September 10 noted that the U.S.-listed shares closed at $44.56 on September 9, nearer their 12-month low of $35.12 than their high of $64.16. The preview put total Wegovy pill prescriptions past five million, with the latest million added in four weeks, and the pill's share of the U.S. oral obesity market at about 90%. It also pointed to a U.S. obesity decision on CagriSema at the end of 2026 and to semaglutide losing exclusivity in markets such as Canada and Brazil in the second half of 2026. The event follows Novo's announcement that it will drop 'Nordisk' from its name in day-to-day use.
Novo Nordisk announced on Monday, September 14, 2026 that it will use 'Novo' as its day-to-day company name, while Novo Nordisk A/S remains its legal name. The rebrand introduces the platform 'Lasting Health Starts Now,' an updated version of the Apis bull logo, and a culture framework called The Novo Way, built on customer obsession, competitiveness, clarity, and care and integrity. CEO Mike Doustdar said healthcare "must become more responsive, relevant and easier to fit into everyday life." The company said it would present more detail on its strategy at its Capital Markets Day in London on September 21, 2026.
Novo Nordisk and Anthropic announced on Wednesday, September 16, 2026 a collaboration under which Novo Nordisk will test Anthropic's Claude Science in specific research and development workflows and use Anthropic's frontier models for biological reasoning, drug discovery, and AI-driven software development. Financial terms were not disclosed. Novo Nordisk CEO Mike Doustdar said AI can help the company increase R&D productivity and "compress the path from research to marketed product." Anthropic co-founder and CEO Dario Amodei said giving researchers access to frontier models can shorten research timelines.
Novo Nordisk said on Wednesday, September 16, 2026 that it will present 44 abstracts at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, from September 28 to October 2. The OCTANE study will report real-world data on Wegovy pill use, including weight outcomes, treatment switching, and patient-reported outcomes. Other presentations cover Wegovy 7.2 mg; CagriSema (cagrilintide plus semaglutide) data on appetite regulation, eating behavior, body composition, and bone remodeling from the REDEFINE and REIMAGINE programs; and zenagamtide, the unimolecular GLP-1 and amylin receptor agonist formerly called amycretin.
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) heads into the week of September 14-19, 2026 with the September 21 Capital Markets Day in London one week away, and Friday September 11 fresh in investor minds. Morgan Stanley analyst Thibault Boutherin had cut Novo Nordisk to Underweight from Equal-weight Friday with a DKK 250 price target (implying more than 10% downside) citing subdued mid-term growth outlook plus concerns about the semaglutide loss-of-exclusivity beginning 2031 (semaglutide accounts for approximately 75% of Novo's 2026 sales). HSBC on Wednesday September 9 had raised its price target to DKK 320 (Hold), and Barclays on September 8 had trimmed its target to DKK 300 (Equal Weight). Novo shares closed the prior week down 2.8% in Copenhagen at DKK 278.2. The London Capital Markets Day is expected to unveil fresh strategic ambitions to replace existing targets, plus pipeline detail on CagriSema (cagrilintide + semaglutide) after the February 2026 Redefine-1 head-to-head miss versus Zepbound (23% vs 25.5% weight loss), amycretin (GLP-1/amylin unimolecular dual agonist Phase 3 planning), and the post-semaglutide non-GLP-1 diversification story after the September 7 HERMES + ATHENA ziltivekimab heart-failure trial terminations.
Morgan Stanley analyst Thibault Boutherin and team cut Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) to Underweight from Equal-weight on Friday September 11, 2026, with a DKK 250 price target implying more than 10% downside from current levels. The downgrade thesis: Novo's current valuation does not fully reflect the subdued mid-term growth outlook or the semaglutide patent-cliff implications on the company's terminal value. Semaglutide is expected to account for approximately 75% of Novo's 2026 sales; loss of exclusivity begins in 2031 across major markets. Morgan Stanley also flagged weaker momentum in U.S. Wegovy pill prescriptions following a stronger first half of 2026. Novo shares closed the week down 2.8% in Copenhagen at DKK 278.2 and 3.1% in Frankfurt at EUR 36.89. HSBC on Wednesday September 9 had raised its price target to DKK 320 (from DKK 300) while maintaining a Hold rating, framing the analyst split. Barclays cut its price target to DKK 300 from DKK 310 September 8 following the STEP Young + ziltivekimab HERMES/ATHENA split announcement, and Guggenheim earlier moved its target on Roivant/Pulmovant PHocus success. Novo executed DKK 9.02 billion of the DKK 15 billion share repurchase through September 4.
The oral GLP-1 launch race entered its ninth month with Novo Nordisk's Wegovy pill (oral semaglutide 25 mg for chronic weight management, U.S. launch January 5, 2026) reaching approximately 183,000 weekly total scripts per the most recent IQVIA week ending September 5, 2026 — the highest weekly total since launch. Eli Lilly's Foundayo (orforglipron, once-daily oral small-molecule non-peptide GLP-1 receptor agonist, U.S. launch April 2026) continued its own prescription climb through the same reporting window. Both products are indicated for adults with obesity or overweight with weight-related comorbidities. Wegovy pill's climb reflects continued Medicare Part D coverage expansion following the November 2025 pricing agreement (Ozempic Pill / Wegovy pill at $149/month per the deal) and CMS 2026 formulary guidance. Foundayo pricing on TrumpRx and cash-pay LillyDirect anchors at $149/month at starting doses. The concurrent oral launch trajectories are the largest test to date of oral incretin adoption relative to the established weekly-injectable class dominated by injectable Wegovy and Zepbound.
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) shares closed at DKK 298.95 in Copenhagen on Monday September 7, 2026 (roughly 1.9% below Friday) after the company's simultaneous release of STEP Young Phase 3 pediatric semaglutide data (40.4% of children aged 6 to under 12 achieved BMI below the obesity threshold at week 68 versus 0% placebo) and confirmation that the HERMES and ATHENA Phase 3 ziltivekimab (anti-IL-6 monoclonal antibody) heart-failure trials had been terminated early after a data monitoring committee ruled the studies unlikely to succeed. Barclays' James Gordon cut the Novo Nordisk price target from DKK 310 to DKK 300 while maintaining an Equal Weight rating. Analyst commentary broadly framed the day as a scientific-engine-versus-diversification tension: the semaglutide franchise continues to add indication paths (pediatric obesity below 12 years is one of the last major label extensions available), while the non-GLP-1 diversification story tied to ziltivekimab now depends primarily on the post-acute heart-failure study that remains ongoing. Detailed STEP Young results will be presented at ObesityWeek 2026 in Washington DC November 14-17.
Novo Nordisk (NYSE: NVO) announced Monday September 7, 2026 first results from STEP Young, a Phase 3 randomized double-blind placebo-controlled multinational trial evaluating once-weekly semaglutide combined with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity. The trial enrolled 165 children, dosed with a maximum of 1.7 mg or 2.4 mg semaglutide based on baseline weight. At week 68, 40.4% of the semaglutide group had a BMI below the obesity threshold versus 0% in the placebo group; more than 85% of enrolled children had class II or III severe obesity (BMI ≥35 or ≥40 by adult equivalents) at baseline. Safety and tolerability were consistent with adult and adolescent trials with no new safety concerns and no signals related to growth or pubertal development. Detailed results will be presented at ObesityWeek 2026 in Washington DC November 14-17. Wegovy is currently approved in the U.S. for adolescents 12 and older; a supplemental submission for children under 12 has not been announced.
Novo Nordisk (NYSE: NVO) confirmed Monday September 7, 2026 that it had informed investigators on Friday September 4 that the HERMES and ATHENA Phase 3 trials of ziltivekimab (an anti-IL-6 monoclonal antibody) would end early on the recommendation of an independent data monitoring committee that judged the studies unlikely to succeed. HERMES evaluated ziltivekimab against time to first occurrence of heart failure endpoints including cardiovascular death and heart-failure-linked hospitalisation or urgent visits; ATHENA evaluated the drug's effect on quality of life and other heart-failure-specific measures. The terminations follow the June 2026 ZEUS trial miss (chronic kidney disease plus cardiovascular disease) reported at the ESC Congress August 30, where ziltivekimab lowered inflammation markers but did not reduce major adverse cardiovascular events. A separate post-acute heart failure study of ziltivekimab remains ongoing. Novo shares finished down about 2% on the announcement day (Copenhagen trading open; NYSE closed for Labor Day), with the pediatric semaglutide win offset by the further narrowing of the company's non-GLP-1 growth options.
Novo Nordisk (NYSE: NVO) commercially launched Wegovy pill (oral semaglutide 25 mg for chronic weight management) in Germany on Tuesday September 1, 2026, the first European market for the once-daily oral obesity formulation after the U.S. launch in January 2026. Wegovy pill was FDA-approved in December 2025 as the first oral GLP-1 receptor agonist for obesity, and has topped 5 million cumulative U.S. prescriptions in the first 8 months per Novo Nordisk H1 2026 disclosures. The German launch positions Wegovy pill against Eli Lilly's Foundayo (orforglipron, small-molecule oral GLP-1) which received FDA approval April 1, 2026 and is preparing for European launch pending EMA review. The oral formulation is intended to address patient-preference research showing that 71% of adults with obesity prefer a daily pill over a weekly injection when taking prescription weight-loss medication. Under the German AMNOG process, national reimbursement negotiation will follow marketing launch over the next 6-12 months.
Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.
H1 2026 GLP-1 franchise reporting places Eli Lilly (NYSE: LLY) tirzepatide (Mounjaro plus Zepbound) at nearly $27.7 billion in first-half revenue, an 88% year-over-year increase, versus Novo Nordisk (NYSE: NVO) semaglutide (Ozempic plus Wegovy plus Rybelsus plus Wegovy pill) at approximately $17.5 billion. The revenue gap between the two GLP-1 leaders has widened from under $2 billion at the same point last year to $10.2 billion, driven by Zepbound share gains in U.S. obesity following SURMOUNT-5 superiority data over Wegovy, Mounjaro upside in international markets (China +93% CER, Rest of World +136%), Foundayo (orforglipron) first commercial quarter contribution of $98 million, and semaglutide patent expiries approaching in select markets (generic Ozempic expected in Canada). Novo has cut 12,000 positions in H1 2026 and lowered gross margin outlook to 78%, while Lilly raised full-year 2026 revenue guidance to $85-87 billion.
Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.